Propanc Biopharma Concludes Development of a Method of the Bio-analytical Assessment to Quantify Active Ingredients of PRP in Preparation for First-In-Human Study

Propanc Biopharma, (also Propanc), a biopharmaceutical firm which is developing new cancer treatments for patients with recurrent and metastatic cancer, today announced that it has created a technique for quantifying the active components of the lead item candidate of Propanc, PRP, in preparing for the First-In-Human (“FIH”) research by the company. It is scheduled for early 2020. Propanc’s study partner based in Berlin, Germany, performed the job, having comprehensive expertise in developing functional assays for distinctive bio-therapeutics. The development and validation of this bioanalytical technique play an important role in assessing and interpreting the systemic absorption of PRP in clinical studies including its distribution and clinical impacts throughout the body.

PRP is a combination of two intravenous proenzymes, trypsinogen and chymotrypsinogen. Naturally derived proenzymes are very big and complicated protein structures which can be broken down into various pieces which can be hard to distinguish and evaluate from human serum. Due to the close structural resemblance of each protein structure, the notable accomplishment in identifying and developing an appropriate technique for measuring four main PRP analytes, the two proenzymes, trypsinogen and chymotrypsinogen, as well as the activated enzymes, trypsin and chymotrypsin, is especially important. An appropriate technique was created to separate, recognize and quantify all four analytes by using an extremely delicate detection scheme such as Liquid Chromatography / Mass Spectrometry. Also, a powerful correlation between concentration and signal intensity was created with an R 2= 0.9996, where 1.0000 is a linear, straight-line showing a direct correlation between the two measured factors. This is particularly crucial when measuring analyte concentration over time within a certain range, offering useful data about the dosage and clinical impacts of a drug when administered to patients, such as PRP. Lower quantification and detection limits have also been set.